Key clinical point: A new tool specifically designed to evaluate immune checkpoint inhibitor–related toxicity, developed based on direct patient involvement, picks up on cutaneous and other side effects.
Major finding: The toxicity subscale asks patients to rate 25 items on a scale of 0 (not at all) to 4 (very much).
Study details: Data based on input from 37 cancer patients being treated with immune checkpoint inhibitors and 16 physicians.
Disclosures: The study was supported by a grant from the University of Toronto. Authors of the study provided disclosures related to Merck, Bristol-Myers Squibb, Karyopharm, Boston Biomedical, Novartis, Genentech, Hoffmann La Roche, GlaxoSmithKline, and others.
Hansen AR et al. Cancer. 2020. doi: 10.1002/cncr.32692.